Ari David Baron

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 10.9K citations · Full text

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.3K citations · Full text

Hepatology, Medicine, Randomised Phase 3 +11

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke et al. · The Lancet Oncology · 2017 · 1.7K citations

Urology, Metastatic Urothelial Carcinoma, Genitourinary Cancer +6

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu et al. · Journal of Clinical Oncology · 2020 · 1.1K citations · Full text

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 829 citations · Full text

Oncology, Hepatology, Clinical Trials +10